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Introduction: Microvascular alterations impair tissue oxygenation during sepsis. A red blood cell (RBC) transfusion
increases oxygen (O2) delivery but rarely improves tissue O2 uptake in patients with sepsis. Possible causes include
RBC alterations due to prolonged storage or residual leukocyte-derived inflammatory mediators. The aim of this
study was to compare the effects of two types of transfused RBCs on microcirculation in patients with sepsis.
Methods: In a prospective randomized trial, 20 patients with sepsis were divided into two separate groups and
received either non-leukodepleted (n = 10) or leukodepleted (n = 10) RBC transfusions. Microvascular density and
perfusion were assessed with sidestream dark field (SDF) imaging sublingually, before and 1 hour after transfusions.
Thenar tissue O2 saturation (StO2) and tissue hemoglobin index (THI) were determined with near-infrared spectroscopy,
and a vascular occlusion test was performed. The microcirculatory perfused boundary region was assessed in SDF
images as an index of glycocalyx damage, and glycocalyx compounds (syndecan-1, hyaluronan, and heparan sulfate)
were measured in the serum.
Results: No differences were observed in microvascular parameters at baseline and after transfusion between the
groups, except for the proportion of perfused vessels (PPV) and blood flow velocity, which were higher after
transfusion in the leukodepleted group. Microvascular flow index in small vessels (MFI) and blood flow velocity
exhibited different responses to transfusion between the two groups (P = 0.03 and P = 0.04, respectively), with a
positive effect of leukodepleted RBCs. When within-group changes were examined, microcirculatory improvement
was observed only in patients who received leukodepleted RBC transfusion as suggested by the increase in De
Backer score (P = 0.02), perfused vessel density (P = 0.04), PPV (P = 0.01), and MFI (P = 0.04). Blood flow velocity
decreased in the non-leukodepleted group (P = 0.03). THI and StO2 upslope increased in both groups. StO2 and
StO2 downslope increased in patients who received non-leukodepleted RBC transfusions. Syndecan-1 increased
after the transfusion of non-leukodepleted RBCs (P = 0.03).
Conclusions: This study does not show a clear superiority of leukodepleted over non-leukodepleted RBC transfusions
on microvascular perfusion in patients with sepsis, although it suggests a more favorable effect of leukodepleted RBCs
on microcirculatory convective flow. Further studies are needed to confirm these findings.
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Anemia is a common problem in intensive care units (ICUs)
[1]. Red blood cell (RBC) transfusion aimed at increasing O2
delivery is generally considered a life-saving treatment [2].
Nonetheless, a restrictive transfusion strategy may result in
equivalent or improved clinical outcomes in comparison
with liberal transfusion strategies [3]. This raises concern
whether transfusion practice is beneficial in general.
Altered properties of stored blood products might ex-
plain this paradoxical effect. Biochemical and hemor-
rheological alterations of packed RBC units due to
prolonged storage (depletion of ATP and 2,3-diphospho-
glycerate, membrane phospholipid vesiculation and loss,
protein and lipid peroxidation, and loss of deformability)
[4-6] may affect their O2 delivery capacity [7-9]. Residual
leukocytes in RBC units may also compromise the effi-
cacy of blood transfusion by producing cytokines such
as interleukin (IL)-1b, IL6, IL8, and tumor necrosis
factor-alpha (TNFα), which may interfere with immune
function [10], alter circulating lymphocytes, and enhance
neutrophil activity in recipients [11,12]. These effects,
collectively referred to as “transfusion-related immuno-
modulation”, may be responsible for higher incidences
of infections among transfused patients [13]. Moreover,
cytokines may contribute to RBC membrane alterations
during storage [14] and impair RBC rheology. These ef-
fects, in theory, should be prevented by leukocyte reduc-
tion; however, clinical data remain controversial [15].
The effects of blood transfusion in patients with sepsis,
and in particular how it influences tissue microcirculation,
are poorly understood. Sepsis-induced microvascular dys-
function [16], endothelial and glycocalyx damage [17], and
pathological shunting and heterogeneous perfusion [18]
may hamper blood transfusion-based restoration of tissue
RBC delivery and oxygenation [19]. Moreover, altered
RBCs or inflammatory mediators in blood bags (or both)
may further compromise microvascular perfusion and tis-
sue O2 uptake. Only a few studies have previously investi-
gated the response of the microcirculation to blood
transfusion in septic populations [20-22] and found no glo-
bal effect on microvascular perfusion; unfortunately, how-
ever, the characteristics of the transfused RBCs in these
studies were not examined. The primary aim of the present
study was to compare the effects of non-leukodepleted or
leukodepleted RBC transfusions on microvascular flow in
patients with sepsis. In addition, it was determined whether
transfusion of either non-leukodepleted or leukodepleted
packed RBC units could increase microcirculatory density
and reactivity to improve tissue oxygenation during sepsis.
Materials and methods
The study protocol was approved by the local medical eth-
ics committee of the Azienda Ospedaliero Universitaria
(AOU) Ospedali Riuniti of Ancona in Italy (NCT01584999,www.clinicaltrials.gov). Written informed consent was ob-
tained from the enrolled patients or their next of kin.
Patients
Between February 2011 and 2012, adult patients admit-
ted to the 12-bed ICU of the AOU Ospedali Riuniti of
Ancona with sepsis, severe sepsis, or septic shock as di-
agnosed according to standard criteria [23] and requir-
ing blood transfusion for hemoglobin (Hb) levels of less
than 8 g/dL or as indicated by the attending physician
(in accordance with the local hospital guidelines) were
eligible to participate in this prospective randomized
study. Exclusion criteria for this study were age of less
than 18 years, previous blood transfusions during ICU
stay, previous history of coagulation disorders, cardio-
genic or hemorrhagic shock, pregnancy, and factors im-
peding the sublingual microcirculation evaluation (oral
surgery and maxillofacial trauma). All patients were moni-
tored with an arterial catheter. Sedation and analgesia
were provided according to individual needs, as well as
the type of fluids infused (crystalloids and colloids) and
adrenergic agents (norepinephrine and dobutamine). The
goal was to maintain a mean blood pressure of 65 mm Hg
as recommended by the international guidelines of the
Surviving Sepsis Campaign (2008) [24]. Fluid infusion and
furosemide treatment were titrated according to individual
needs in order to maintain adequate urine output (>0.5
mL/kg per hour) [24].
Interventions
The original study protocol included three separate
groups of septic patients receiving transfusion of fresh
(<10 days of storage) non-leukodepleted, fresh leukode-
pleted, or old (>15 days of storage) non-leukodepleted
RBC units, respectively. The analysis presented herein
was focused on the role of leukocyte reduction; there-
fore, only the data from the first two groups (hereafter
referred to as non-leukodepleted and leukodepleted
groups) are reported. A parallel analysis focused on the
role of prolonged storage will be reported separately.
Blood product randomization was performed through
sealed envelopes by a physician at the blood bank, who
blindly provided the blood bags to the ICU; neither the
attending physician nor the investigators nor the pa-
tients were aware of the type of RBCs transfused. Post-
storage leukoreduction was performed by a blood bank
physician using the filter Sepacell RZ-200 (Fenwal, Inc.,
Lake Zurich, IL, USA) within a maximum of 5 days after
donor blood withdrawal.
Basic hemodynamic and blood gas parameters
All measurements were performed immediately before
and 1 hour after RBC transfusions. These time points
were chosen on the basis of those reported in previous
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and mean arterial pressure (MAP). Arterial blood sam-
ples were withdrawn in order to assess Hb level, whole
blood cell counts, blood gases—pH, arterial partial pres-
sure of oxygen (paO2), arterial partial pressure of carbon
dioxide (paCO2), oxygen saturation (SaO2), paO2/fraction
of inspired oxygen (paO2/FiO2), HCO3
−, base excess—and
lactate (Lac), creatinine, and glucose levels. Arterial blood
samples were immediately centrifuged, and plasma and
serum were stored at −70°C for subsequent analysis. For
each participant, the Simplified Acute Physiology Score
(SAPS) II was obtained at admission and the Sequential
Organ Failure Assessment (SOFA) score [25] on the study
day.
Microcirculation measurements with sidestream dark
field imaging
Sublingual microcirculatory density and flow were mo-
nitored by using sidestream dark field (SDF) imaging
(Microscan; Microvision Medical BV, Amsterdam, The
Netherlands); details on the SDF imaging technique have
been described elsewhere [26]. Briefly, the Microscan is a
hand-held video microscope system that epi-illuminates a
tissue of interest with stroboscopic green (530 nm) light-
emitting diodes. Hb absorbs the 530 nm wavelength light,
which in turn is captured via the imaging probe’s light
guide and a charge-coupled device camera. Clear images
of flowing RBCs are depicted as dark moving globules in
the lumen of blood vessels against a white/grayish back-
ground. After the removal of saliva and other secretions
with a gauze, the SDF probe, covered by a sterile dispos-
able cap, was gently applied on the sublingual mucosa of
the floor of the mouth at the base of the tongue. Videos
from five different sites (at least 10 seconds per site) were
recorded at both time points with adequate focus and con-
trast, and every effort was made to avoid movement and
pressure artefacts. Poor-quality images were discarded,
and three images for each time point were selected and
analyzed by using a computer software package (Auto-
mated Vascular Analysis Software; Microvision Medical
BV). According to the consensus report on the perform-
ance and evaluation of microcirculation using SDF im-
aging [27], total vessel density (TVD) and perfused vessel
density (PVD) were calculated for small vessels (diameter
of less than 20 μm). The De Backer score was calculated
as described previously [27]. In brief, the SDF image was
divided by three equidistant horizontal and three equidis-
tant vertical lines; the De Backer Score was calculated as
the number of the small (diameter of less than 20 μm) and
medium (diameter of 20 to 100 μm) vessels crossing the
lines divided by the total length of the lines. The propor-
tion of perfused vessels (PPV) and the microvascular flow
index (MFI), reflecting microcirculatory blood flow vel-
ocity, were analyzed semi-quantitatively in small vessels,as described elsewhere [28]. The flow heterogeneity index
was also calculated as the highest MFI minus the lowest
MFI, divided by the mean MFI, providing an index of het-
erogeneous microcirculatory perfusion. Quantitative blood
flow velocity was measured through the use of space-time
diagrams [29]. Three lines were manually traced in the
space-time diagram, and the average orientation was used
to calculate the blood flow velocity [30].
Peripheral O2 and hemoglobin measurements with
near-infrared spectroscopy
Near-infrared reflectance spectrophotometry (InSpectra™
Model 650; Hutchinson Technology Inc., Hutchinson,
MN, USA) was used to measure peripheral tissue oxygen
saturation (StO2) and tissue Hb index (THI) [31,32] at
baseline and during a vascular occlusion test (VOT). A
15 mm-sized probe was placed on the skin of the thenar
eminence, and a sphygmomanometer cuff was placed
around the (upper) arm to occlude the brachial artery.
After a 3-minute period of StO2 signal stabilization, ar-
terial inflow was arrested by inflation of the cuff to 50
mm Hg above the systolic arterial pressure. The cuff was
kept inflated until the StO2 decreased to 40% and then
released [33]. StO2 was continuously recorded during
the reperfusion phase until stabilization [33]. The StO2
downslope (%/minute) was calculated from the regres-
sion line of the first minute of StO2 decay after occlu-
sion, providing an index of O2 consumption rate. The
StO2 upslope (%/minute) was obtained from the regres-
sion line of StO2 increase in the reperfusion phase. The
area under the curve (AUC) of the hyperemic response
was also calculated. StO2 upslope and the AUC of the
StO2 reflect microvascular reactivity [33]. All the param-
eters were calculated by using a computer software
package (version 3.03 InSpectra Analysis Program;
Hutchinson Technology Inc.).
Microvascular glycocalyx assessment
A series of 10 Microscan video fragments of at least 40
consecutive frames were automatically analyzed by using
the GlycoCheck ICU software package (Maastricht Uni-
versity Medical Center, Maastricht, The Netherlands) in
order to measure vascular lumen perfused boundary re-
gion (PBR). The PBR includes the dimension of the per-
meable part of the endothelial glycocalyx which allows
the penetration of flowing RBCs. Erythrocytes usually
have limited access into an intact glycocalyx; when this
is compromised and starts losing its protective capacity,
its permeability increases, allowing circulating cells to
approximate the luminal endothelial membrane. As a re-
sult, the dimension of the erythrocyte PBR will increase
[34]. This methodology has been extensively described
elsewhere [35]. Briefly, measurement lines perpendicular
to the vessel direction are arranged automatically every





n = 10 n = 10
Age, years 70 (65–72) 74 (64–79)
Sex, male; female 5; 5 7; 3
SAPS II on admission 37 (28–74) 41 (35–47)
ICU days before enrollment 9 (8–12) 9 (4–29)
Sepsis, number 2 5
Severe sepsis, number 3 2
Septic shock, number 5 3
Source of infection, number
Lung 4 3
Abdomen 1 3
Urinary tract 2 1
Miscellaneous 3 3
Adrenergic dosea
Norepinephrine 5; 0.047 (0.015–0.370) 3; 0.155 (0.050–0.260)
Dobutamine 1; 2.074 (2.074–2.074) 1; 2.31 (2.31–2.31)
aNumber of patients; median dose in μg/kg*min (interquartile range). ICU,
intensive care unit; SAPS II, Simplified Acute Physiology Score II.
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than 50 μm. Each line represents a measurement site; at
each measurement site, 21 parallel (every 0.5 μm) intensity
profiles are plotted, and RBC column width (full width
half maximum) is determined at each line for all 40 con-
secutive frames in a movie, revealing a total of 840 RBC
column width measurements at a measurement site (21
profiles × 40 frames). The associated (cumulative) distribu-
tion of the RBC column widths for these 840 measure-
ments was used to determine median RBC column width
(P50) as well as lower and upper percentiles of the RBC
column width distribution. The RBC perfused diameter
(position of the outer edge of the RBC perfused lumen) is
derived from the RBC column width distribution by linear
extrapolation of all RBC column width percentiles be-
tween P25 and P75. The PBR is defined as the distance of
median (P50) RBC column width to the outer edge of the
extrapolated RBC perfused diameter.
Serum measurements of glycocalyx damage markers
Concentrations of syndecan-1 (Human sCD138/Synde-
can-1 enzyme-linked immunosorbent assay [ELISA] Gen-
Probe Diaclone SAS, Besancon, France), heparan sulfate
(Human heparan sulfate HS ELISA Kit; Cusabio Biotech
Co., Ltd., Wuhan, Hubei Province 430206, China), and
hyaluronan (Hyaluronic Acid Quantitative Test kit;
Corgenix, Inc., Broomfield, CO, USA), three main compo-
nents of the endothelial glycocalyx [36], were measured in
serum by using the corresponding ELISA kits in accord-
ance with the instructions of the manufacturer.
Sample size calculation
Sample size calculation was computed on the basis of MFI
data. A total of nine patients per group was shown to be
sufficient to detect a statistically significant change in MFI
of 0.4 (standard deviation = 0.3) after blood transfusion
with a power of 80% and an alpha error of 0.05.
Statistical analysis
Statistical analysis was performed by using GraphPad Prism
version 5 (GraphPad Software, La Jolla, CA, USA). A
Mann-Whitney U test was used to evaluate differences be-
tween the two groups at baseline and after blood transfu-
sion. Wilcoxon matched-pairs signed-rank test was used for
comparative analysis of data sets obtained before and 1 hour
after RBC transfusion. A Spearman coefficient was evalu-
ated to study the correlation between variables. All data are
presented as median (25th-75th percentiles). Differences
were considered significant at P values of less than 0.05.
Results
Twenty patients were enrolled in the study (10 patients
per group). Patient characteristics are presented in
Table 1. All patients were mechanically ventilated. Allpatients received 2 (2 to 3) packed RBC units, and all
transfused RBCs were fresh: median ages were 4 (3.5 to
5) days for non-leukodepleted and 3 (1.5 to 3) days for
leukodepleted RBCs.
Sequential Organ Failure Assessment score, hematologic,
hemodynamic, and gas exchange variables
SOFA score, hematologic, hemodynamic and gas exchange
variables before and 1 hour after blood transfusion are pre-
sented in Table 2. Hb and hematocrit increased after blood
transfusion in both groups (P <0.01). After blood transfu-
sion, a decrease in base excess was found only in the non-
leukodepleted group (P <0.05). Baseline MAP and PaO2/
FiO2 were lower in the non-leukodepleted group compared
with the leukodepleted group. MAP increased after transfu-
sion only in the non-leukodepleted group (P = 0.04). No
other significant differences between groups or time points
were found.
Sidestream dark field- and near-infrared spectroscopy-derived
variables
Microcirculatory and near-infrared spectroscopy (NIRS)-
derived variables before and 1 hour after blood trans-
fusion are presented in Table 3. When groups were
compared, at baseline there were no statistically signifi-
cant differences, but after transfusion, higher PPV and
blood flow velocity were observed in the leukodepleted
group (Figure 1). Concerning the changes between before
and after transfusion, MFI and blood flow velocity exhi-
bited different responses—MFI: −0.02 (−0.1 to 0.04) in the
non-leukodepleted group and 0.17 (0 to 0.54) in the
Table 2 Hematologic, hemodynamic, and gas exchange variables and Sequential Organ Failure Assessment score
(baseline and 1 hour after blood transfusion)
Non-leukodepleted group Leukodepleted group
n = 10 n = 10
Before After Pa Before After Pa
Hb, g/dL 8.4 (7.9–8.8) 10.4 (9.9–11.5) <0.01 8.3 (7.4–8.6) 10.4 (9.9–10.8) <0.01
Hct, % 26.7 (26.0–28.0) 32.5 (29.9–34.6) <0.01 25.9 (22.9–27.9) 31.5 (29.5–33.5) <0.01
HR, bpm 72 (59–98) 70 (60–86) 0.20 91 (79–97) 88 (81–94) 0.60
MAP, mm Hg 70 (67–77) 77 (72–98) 0.04 85 (75–106)b 89 (78–96) 0.68
Urine output, mL/d 3,145 (2,516–3,625) 3,572 (2,385–4,266) 0.99 3,520 (2,756–4,854) 4,636 (2,967–5,314) 0.07
T, °C 36.8 (35.9–37.3) 36.7 (36.1–37.4) 0.48 36.9 (36.5–37.4) 37.4 (36.5–37.9) 0.12
WBCs, ×103/μL 11.9 (5.2–17.3) 12.5 (5.1–17.2) 0.99 8.7 (5.9–15.4) 8.6 (6.6–13.3) 0.76
PLTs, ×103/μL 190 (112–225) 198 (87–216) 0.86 163 (90–336) 172 (100–332) 0.27
pH 7.48 (7.36–7.54) 7.49 (7.37–7.52) 0.07 7.48 (7.46–7.5) 7.48 (7.47–7.50) 0.99
PaO2, mm Hg 123 (103–149) 105 (96–125) 0.06 133 (94–183) 137 (119–153) 0.41
PaCO2, mm Hg 42 (36–45) 42 (37–46) 0.94 39 (34–41) 39 (35–41) 0.76
PaO2/FiO2 230 (206–309) 215 (173–298) 0.36 323 (243–408)
b 287 (270–374) 0.34
BE, mEq/L 5.7 (1.8–10.5) 5.3 (1.3–9.5) 0.03 3.7 (2.8–5.9) 3.9 (2.2–5.8) 0.73
Lac, mmol/L 1.2 (0.9–1.7) 1.3 (1.0–1.8) 0.44 1 (0.7–1.4) 1.1 (0.7–1.4) 0.53
SOFA score 8 (5–12) 8 (3.4–12) 0.85 5 (3–7) 5 (3–8) 0.59
aPre versus post, Wilcoxon matched–pairs signed–rank test. bP <0.05, versus non–leukodepleted red blood cell group at the same time point, Mann–Whitney U
test. BE, base excess; FiO2, fraction of inspired oxygen; Hb, hemoglobin; Hct, hematocrit; HR, heart rate; Lac, arterial lactate levels; MAP, mean arterial pressure;
PaCO2, arterial partial pressure of carbon dioxide; PaO2, arterial partial pressure of oxygen; PLT, platelet; SOFA, Sequential Organ Failure Assessment; T, body
temperature; WBC, white blood cell.
Donati et al. Critical Care 2014, 18:R33 Page 5 of 11
http://ccforum.com/content/18/1/R33leukodepleted group, P = 0.03; blood flow velocity: −56
(−183 to 16) in the non-leukodepleted group and 68 (11
to 170) in the leukodepleted group, P = 0.04. When look-
ing at within-group changes, compared with baseline,
MFI, PVDs, PPV, and De Backer score increased in pa-
tients who received leukodepleted RBCs but not in those
who received non-leukodepleted RBCs (Figure 1). Blood
flow velocity decreased only in the non-leukodepleted
group (Figure 1). No correlation was found between
changes in microvascular parameters and MAP after
blood transfusion. The change in PPV after blood
transfusion was negatively correlated with baseline PPV in
the leukodepleted group (r = −0.72, P = 0.02); this rela-
tionship was lacking in the non-leukodepleted group
(r = −0.36, P = 0.3).
No significant differences were observed in NIRS-
derived parameters at baseline and after transfusion. In
regard to within-group changes, StO2 upslope and THI
were elevated in both groups (Figure 2C). Baseline StO2
(Figure 2A) and StO2 downslope (Figure 2B) increased
in the non-leukodepleted group. No difference in the
AUC for StO2 was found in either the between-group or
the within-group analysis.
Glycocalyx measurements
Baseline heparan sulfate was higher in the leukodepleted
group, and no significant differences were observed forbaseline syndecan-1, hyaluronan, and PBR between the
groups. After blood transfusion, PBR, heparan sulfate,
and hyaluronan did not change between the two groups
(Figure 3). Syndecan-1 increased after the transfusion of
non-leukodepleted RBCs (Figure 3B). A minor correl-
ation was found between PBR values and heparan sulfate
levels (r = 0.35, P = 0.03) as well as between PBR changes
and heparan sulfate changes after blood transfusion in
the whole sample (r = 0.46, P = 0.04) (Figure 4). No cor-
relation was found between PBR values and syndecan-1
or hyaluronan levels.
Discussion
The present study does not show a clear superiority of leu-
kodepleted over non-leukodepleted RBC transfusion on
microvascular perfusion in patients with sepsis, but the
more favorable changes observed in MFI and blood flow
velocity suggest a positive effect of leukodepleted blood
transfusion on microcirculatory convective flow. The
within-group analysis indicates that patients who received
leukodepleted RBCs exhibited a more consistent overall
improvement in the microvascular parameters. The lack
of further differences in the between-group comparisons
may just reflect that the study was underpowered.
The sublingual microcirculation is used as a model to
study and extrapolate information representing splanch-
nic blood flow. Persistent microvascular alterations are
Table 3 Microcirculatory parameters, near-infrared spectroscopy-derived variables, and glycocalyx variables
(baseline and 1 hour after blood transfusion)
Non-leukodepleted group Leukodepleted group
n = 10 n = 10
Before After Pa Before After Pa
MFI, AU 2.75 (2.43–2.87) 2.62 (2.38–3.00) 0.73 2.79 (2.37–2.92) 2.96 (2.89–3.00) 0.04
De Backer score, 1/mm 11.3 (9.7–11.8) 11.3 (9.3–14.4) 0.16 9.8 (9.4–10.8) 12.3 (10.6–13.1) 0.02
TVD, mm/mm2 18.4 (16.6–19.8) 19.6 (15.1–23.3) 0.19 15.9 (12.9–19.3) 19.3 (12.8–21.8) 0.08
PVD, mm/mm2 16.2 (14.3–17.7) 17.6 (13.5–21.4) 0.23 14.1 (11.8–17.2) 18.8 (12.1–21.2) 0.04
PPV, % 88.5 (83.1–93.1) 90.6 (85.8–96.6) 0.32 94.6 (82.9–95.9) 96.8 (94.7–98.9)b 0.01
HI 0.23 (0.13–0.50) 0.16 (0.00–0.32) 0.31 0.13 (0.06–0.23) 0.04 (0.00–0.10) 0.11
Blood flow velocity, μm/s 415 (327–494) 291 (264–314) 0.03 314 (267–354) 402 (355–451)b 0.08
THI, AU 10.5 (7.8–11.2) 13.4 (10.4–15.8) <0.01 10.3 (8.6–13.6) 13.8 (10.6–15.7) 0.02
StO2, % 88 (80–90) 90 (85–93) 0.03 83 (77–92) 86 (82–89) 0.59
StO2 down, %/min −9.5 (−11 to −8.5) −9.0 (−10.4 to −7.5) 0.03 −10.1 (−12.8 to −6.9) −9.2 (−10.4 to −7.6) 0.56
StO2 up, %/min 173.6 (81.26–220.4) 191.3 (133.4–242.4) 0.01 197.9 (99.2–260.3) 206.2 (131.1–291.8) 0.03
AUC StO2, %×min 10.7 (8.4–21) 10.9 (8.2–25.4) 0.99 8.0 (4.4–13.8) 12.1 (5.5–18.3) 0.51
PBR, μm 2.69 (2.53–2.94) 2.72 (2.65–2.86) 0.23 2.80 (2.76–2.97) 2.74 (2.58–3.00) 0.73
Syndecan–1, ng/mL 219.4 (84.5–361.5) 310.1 (80.9–498.8) 0.03 100.0 (5.4–378.4) 127.5 (6.6–505.6) 0.37
Heparan sulfate, ng/mL 23.3 (19.7–39.5) 44.7 (9.1–79.2) 0.43 63.1 (40.5–96.0)b 48.7 (39.0–79.2) 0.37
Hyaluronan, ng/mL 211.9 (75–423.7) 198.1 (94.2–320.0) 0.37 275.7 (109.3–450.7) 249.4 (129.2–433.3) 0.32
aPre versus post, Wilcoxon matched–pairs signed–rank test. bP <0.05, versus non–leukodepleted red blood cell group at the same time point, Mann–Whitney U
test. Microvascular flow index (MFI), total vessel density (TVD), perfused vessel density (PVD), proportion of perfused vessels (PPV), and flow heterogeneity index
(HI) were calculated in small vessels (diameter <20 μm). AUC StO2, area under the curve of the tissue oxygen saturation (reactive hyperemia following the vascular
occlusion test); PBR, perfused boundary region; StO2, tissue oxygen saturation; StO2 down, tissue oxygen saturation downslope (ischemic phase of the vascular oc-
clusion test); StO2 up, tissue oxygen saturation upslope (reperfusion phase of the vascular occlusion test); THI, tissue hemoglobin index.
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death in patients with septic shock [37]. Previous studies
showed that blood transfusions were not able to reverse
microcirculatory hypoperfusion in patients with severe
sepsis [20,22]. However, the characteristics of the trans-
fused RBCs, in terms of storage and leukocyte reduction,
were not examined in previous investigations. The pre-
sent study did not demonstrate a clear advantage of leu-
kodepleted over non-leukodepleted RBC transfusion on
the microcirculation. Indeed, the sublingual microvascular
parameters were mostly not significantly different after
transfusion between the two groups, and the difference in
PPV might totally depend on the basal disparity. Never-
theless, the MFI, which was the primary endpoint of the
study, showed significantly different changes after the
transfusion of leukodepleted versus non-leukodepleted
RBC units. Similarly, different effects were observed
through the quantification of blood flow velocity, which
was higher after the transfusion of leukodepleted RBCs.
These results would suggest a beneficial effect of leukode-
pleted blood transfusion on the convective flow in the
microcirculation. Lower adhesiveness to vascular endothe-
lial cells has been reported for leukodepleted compared
with non-leukodepleted and buffy coat-poor blood [38,39]
and may account for a better hemorrheological impact ofleukodepleted RBCs. In addition, the within-group analysis
indicated more consistent improvements in several micro-
vascular parameters in patients who received leukode-
pleted RBCs, as represented by increased microvascular
density and percentage of perfused vessels. The transfu-
sion of non-leukodepleted RBCs did not yield any notable
improvement in the sublingual microcirculation; a reduc-
tion in blood flow velocity was observed. Nevertheless,
several points should be considered. First, the responses
observed may depend not only on the type of transfused
RBCs but also on the underlying clinical and microvascu-
lar status. We studied a heterogeneous population by in-
cluding patients with sepsis, severe sepsis, or septic shock.
Second, the two groups were not adequately balanced; in
fact, the patients in the non-leukodepleted group appeared
to be more severely ill in general as indicated by the lower
MAP and PaO2/FiO2, higher SOFA score (even if not sig-
nificant), and higher proportion of patients with septic
shock. Therefore, definite conclusions cannot be extrapo-
lated from the results of the present study, as the meaning
of any comparison between the groups remains uncertain.
Notably, however, one would have expected the more se-
verely ill patients in the non-leukodepleted group to show
bigger microvascular improvements: indeed, the microcir-
culatory response to blood transfusion demonstrated a
Figure 1 Individual changes in microcirculatory parameters after blood transfusion in non-leukodepleted and leukodepleted groups.
(A) Microcirculatory flow index (in small vessels). (B) Total small vessel density. (C) Perfused small vessel density. (D) Proportion of perfused small
vessels. (E) De Backer score. (F) Blood flow velocity. *P <0.05, Wilcoxon matched-pairs signed-rank test; #P <0.05, Mann-Whitney U test.
Figure 2 Individual changes in near-infrared spectroscopy (NIRS)-derived variables after blood transfusion in non-leukodepleted and
leukodepleted groups. (A) Tissue oxygen saturation (StO2) baseline. (B) StO2 downslope (ischemic phase during the vascular occlusion test).
(C) StO2 upslope (reperfusion phase during the vascular ocllusion test). *P <0.05, Wilcoxon matched-pairs signed-rank test.
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Figure 3 Effects of the transfusion of non-leukodepleted and leukodepleted red blood cells (RBCs) on the endothelial glycocalyx.
(A) Perfused boundary region. (B) Syndecan-1. (C) Heparan sulfate. (D) Hyaluronan. *P <0.05, Wilcoxon matched-pairs signed-rank test; #P <0.05,
Mann-Whitney U test.
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with severe sepsis [20]. In our study, the increase in PPV
was inversely related to baseline values in patients who re-
ceived leukodepleted RBCs; interestingly, this correlation
was lacking in the non-leukodepleted group. Finally, most
patients were studied several days after their ICU admit-
tance and were already hemodynamically stable, as
reflected by their low SOFA score, normal heart rate, low
arterial lactate levels, and absence of metabolic acidosis.
Conversely, metabolic alkalosis was seen in both groups;
the most plausible reason was that 17 patients out of 20
had been treated with furosemide for some days before
their inclusion in the study. Moreover, most patients did
not show big microcirculatory alterations at baseline; PPV
was above 75% in all patients, and the median MFI was
above 2.6 in both groups [30]. This may have conditioned
the response observed. The transfusion of leukodepleted
RBCs was able to improve microvascular perfusion andFigure 4 Correlation between perfused boundary region (PBR) and se
and serum HS values. (B) Correlation between changes in PBR and serum Htissue oxygenation in patients with a relatively healthy
microcirculation [40,41] but did not show any significant
effect in severely septic patients with dysfunctional micro-
circulation [20]. Therefore, our findings could not be
extended to septic patients with severe microvascular
derangement. Moreover, it remains a matter of debate whe-
ther most of our patients with an already-resuscitated
microcirculation really required an increase in microvascu-
lar perfusion and whether such an increase could have any
beneficial impact on outcome.
We found an increase in serum syndecan-1 levels after
the transfusion of non-leukodepleted RBCs, suggesting
fragmentation of the endothelial glycocalyx. The glycoca-
lyx is believed to fulfil an important role in maintaining
microvascular hemorrheological homeostasis. Interestingly
however, it can be easily damaged by oxidative stress and
inflammatory mediators [36,42,43]. We did not find any
change in hyaluronan, heparan sulfate, and PBR in eitherrum heparan sulfate (HS). (A) Correlation between all PBR values
S after blood transfusion.
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after blood transfusion between the groups. Therefore, our
results do not allow any conclusion on the effect of the
transfusion of the two types of RBCs on the glycocalyx.
Large variability was seen in the baseline glycocalyx status
in the studied patients; perhaps in relation to the severity
of sepsis, this heterogeneity may have produced different
responses to blood transfusion.
The transfusion of banked leukodepleted RBCs, stored
up to 42 days, showed no substantial effect on muscle
StO2 and microvascular reactivity in critically ill patients
[21]; similar results were found in severely septic pa-
tients with the transfusion of non-leukodepleted RBCs
stored up to 42 days [22]. Blood transfusions increase
blood viscosity [41], thus leading to shear stress-induced
vasodilation by nitric oxide production [44]. During hyp-
oxia, RBCs can release nitric oxide and ATP, thereby
exerting a direct vasodilator effect [21]; these properties
may be impaired during prolonged storage [4,5]. In the
present study, microvascular reactivity improved after
blood transfusion in both groups, as reflected by the in-
crease in NIRS-derived StO2 upslope during the reperfu-
sion phase of the VOT. We could speculate that the
transfusion of fresh RBCs with preserved hemorrheolo-
gical properties was responsible for the observed effect.
Nevertheless, the discrepancy between our results and
previous findings might reasonably be explained also by
differences in the studied patient populations.
Despite the increase in THI in both groups, StO2 and
StO2 downslope increased only in the non-leukodepleted
group. It should be noted that similar absolute change,
though not significant, was observed in the leukodepleted
group. We acknowledge that this study may have been
underpowered to detect changes in these parameters. An
increase in muscle and sublingual tissue oxygenation was
reported after the transfusion of leukodepleted RBCs in
hematology outpatients [41]. On the contrary, previous
studies in critically ill and severely septic patients did not
show any effect of blood transfusion on tissue oxygenation
measured by the NIRS technique [21,22]. Substantial dif-
ferences in the baseline microvascular status may again
explain these discrepant results.
The transfusion of leukodepleted RBCs has been asso-
ciated with reduced hospital length of stay [45], inci-
dence of infections [46], transfusion-related acute lung
injury [47], and acute kidney injury [48] in various popu-
lations of patients. It has been reported that transfusion
of leukodepleted RBCs is not associated with increased
mortality in patients with septic shock [49]. It has been
demonstrated that pre-storage leukoreduction can pre-
vent the accumulation of cytokines and other infla-
mmatory mediators from residual leukocytes, thereby
avoiding potentially detrimental effects in the recipient
[50-52]. All of these findings derived from studies usingpre-storage leukoreduction. Notably, in our study, RBC
units underwent a post-storage leukoreduction before
transfusion. This procedure does not prevent the accumu-
lation of leukocyte-derived cytokines during the first days
of storage. This might be one of the reasons why we found
only slight differences in the microcirculation after blood
transfusion between the two groups. Unfortunately, we
could not investigate the potential advantages of pre-storage
leukoreduction, since this is not usually performed in our
blood bank. Nevertheless, microvascular improvement ob-
served in the leukodepleted group might also suggest that
post-storage leukoreduction can still prevent deleterious ef-
fects of the transfusion of RBC units containing allogenic
leukocytes. Further studies comparing pre- and post-storage
leukocyte reduction would be needed to clarify this point.
Our study has several limitations that should be consid-
ered when extrapolating the data reported in this clinical
investigation. First, the low number of patients enrolled
may have resulted in underpowered statistical analysis, and
differences in some variables may not have been detected.
Second, the inclusion of patients with different severity of
sepsis could have influenced the microvascular responses to
blood transfusion. Unfortunately, the small sample size did
not allow a post hoc analysis in order to distinguish between
sepsis, severe sepsis, and septic shock subgroups. Our study
was designed to include a heterogeneous population of pa-
tients with different severity of sepsis. Future studies should
be focused on more homogeneous subgroups of patients
with sepsis. Third, the baseline differences observed be-
tween non-leukodepleted and leukodepleted groups pre-
vented a proper between-group comparison; in fact, we
acknowledge that our results are based mostly on a within-
group analysis which cannot reliably support the benefit of
leukodepleted over non-leukodepleted RBCs in patients
with sepsis. Finally, the inclusion of stable septic patients
with an already-restored microvascular perfusion may
represent a limitation of our study; patients with a dysfunc-
tional microcirculation may have revealed a different
response to the same blood transfusions. This point should
be addressed in future studies. Despite these limitations,
our study remains interesting as it provides a comprehen-
sive evaluation of microcirculatory responses to blood
transfusion in a heterogeneous population of patients with
sepsis. As a pilot study on a small number of patients, our
investigation cannot provide conclusive answers, nor was it
aimed at this goal. Our objective was to explore whether
the transfusion of leukodepleted RBCs could provide any
advantage on the microcirculation in patients with sepsis.
Adequately powered studies should be performed in order
to better define the potential benefits observed.
Conclusions
In this pilot study, we were not able to demonstrate a
clear benefit of leukodepleted over non-leukodepleted
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sepsis. However, our results suggest a more favorable ef-
fect of leukodepleted RBCs on microcirculatory convect-
ive flow. In addition, the within-group analysis showed
more consistent improvements in several microvascular
parameters in patients who received leukodepleted
RBCs. The lack of further differences in the between-
group comparisons may just reflect that the study was
underpowered. Further studies are needed to confirm
these findings.
Key messages
 No clear difference was found in most
microvascular parameters after the transfusion of
leukodepleted or non-leukodepleted red blood cells
(RBCs) in our small and heterogeneous population
of patients with sepsis.
 The transfusion of leukodepleted RBCs compared with
non-leukodepleted RBCs showed a more favorable
effect on microvascular flow index and blood flow
velocity, suggesting a benefit on microcirculatory
convective flow.
 In the within-group analysis, an overall microvascular
improvement was seen only in patients who received
leukodepleted RBC transfusion.
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